Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 4.36M | 4.35M | 2.43M | 377.00K | 500.00K | 0.00 |
Gross Profit | -2.81M | -3.92M | -6.05M | -3.24M | -85.00K | 0.00 |
EBITDA | -54.36M | -44.34M | -49.75M | -54.23M | -27.41M | 482.00 |
Net Income | -55.26M | -45.53M | -52.67M | -56.17M | -28.08M | -8.28M |
Balance Sheet | ||||||
Total Assets | 38.67M | 30.71M | 27.27M | 32.51M | 59.00M | 2.19M |
Cash, Cash Equivalents and Short-Term Investments | 31.12M | 22.36M | 18.90M | 22.47M | 53.66M | 111.25K |
Total Debt | 27.55M | 21.25M | 15.26M | 2.00M | 0.00 | 0.00 |
Total Liabilities | 30.81M | 25.32M | 29.58M | 9.46M | 4.26M | 15.71M |
Stockholders Equity | 7.86M | 5.39M | -2.31M | 23.05M | 54.74M | -13.52M |
Cash Flow | ||||||
Free Cash Flow | -23.03B | -44.79M | -33.04M | -30.59M | -18.53M | -5.63M |
Operating Cash Flow | -23.03B | -44.14M | -32.82M | -29.68M | -17.67M | -5.63M |
Investing Cash Flow | -118.61M | -646.00K | -221.00K | -4.11M | -862.00K | 0.00 |
Financing Cash Flow | 16.49B | 48.25M | 29.46M | 2.61M | 72.08M | 5.58M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $84.74M | ― | -9.80% | ― | 15.16% | -39.18% | |
51 Neutral | $7.44B | -0.20 | -46.00% | 2.26% | 22.80% | -2.27% | |
48 Neutral | $138.74M | ― | 60.56% | ― | 36.81% | -74.26% | |
47 Neutral | $106.43M | ― | -463.56% | ― | 14.74% | 14.63% | |
45 Neutral | $154.39M | ― | -935.73% | ― | 38.32% | -1.31% | |
45 Neutral | $64.79M | ― | -66.88% | ― | 18.24% | 4.81% |
Lucid Diagnostics reported financial results for the second quarter of 2025, with revenue of $1.2 million from 2,756 processed EsoGuard tests. The company ended the quarter with over $30 million in cash, extending its financial runway into 2026. Lucid is advancing towards securing Medicare coverage for EsoGuard, with a significant advisory committee meeting scheduled for September 4, 2025. The company has also initiated testing under a new insurance policy and partnered with Hoag to expand access to its testing programs. Additionally, Lucid joined the Russell 2000 and 3000 Indexes, enhancing its visibility among institutional investors.
The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
On June 18, 2025, Lucid Diagnostics Inc. held its annual meeting of stockholders, where approximately 70.9% of the shares were represented. During the meeting, the stockholders elected management’s nominees for director and approved other key proposals, including the issuance of common stock under the 2024 Convertible Notes and the ratification of CBIZ CPAs P.C. as the company’s independent accounting firm for 2025. These approvals are expected to support Lucid Diagnostics’ strategic initiatives and strengthen its financial and operational framework.
The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
On May 30, 2025, Lucid Diagnostics Inc. entered into a Sales Agreement with Maxim Group LLC to offer and sell up to $25,000,000 of its common stock through an at-the-market offering. The proceeds from this offering are intended for working capital and general corporate purposes, potentially impacting the company’s operational capabilities and market positioning.
The most recent analyst rating on (LUCD) stock is a Buy with a $2.50 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.